drug

Genentech Signs an Exclusive License Agreement with X-Chem to Discover Oncology Targets

Shots: X-Chem to receive an up front and is eligible to receive research, development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration Genentech will lead further development and commercialization of any potential new therapies and retain exclusive rights to compounds derived from the collaboration. Additionally, Genentech get an exclusive …

Genentech Signs an Exclusive License Agreement with X-Chem to Discover Oncology Targets Read More »

Lilly Signs a License Agreement with Asahi Kasei Pharma for AK1780 to Treat Chronic Pain

Shots: Asahi Kasei to receive an $20M up front, ~$210M as development & regulatory milestones and will be eligible for ~$180M milestones along with royalties on sales of the therapy. Lilly to acquire the exclusive rights for AK1780 while Asahi Kasei will retain the right to promote AK1780 in Japan and China (including Hong Kong …

Lilly Signs a License Agreement with Asahi Kasei Pharma for AK1780 to Treat Chronic Pain Read More »

Vertex Reports Health Canada’s Acceptance of Trikafta’s NDA for Priority Review to Treat Cystic Fibrosis

Shots: Vertex’ new drug submission for Trikafta has been accepted for Priority Review by Health Canada for the treatment of CF in people aged ≥12yrs. With PR, the conventional review timeline of 300 days is reduced to 180 days. The expected Health Canada’s approval is in H1’21 Trikafta is a triple combination regimen used to …

Vertex Reports Health Canada’s Acceptance of Trikafta’s NDA for Priority Review to Treat Cystic Fibrosis Read More »

Merck Signs a ~$1B Pact with Janux to Develop Cancer Therapies Using T Cell Engager Technology

Shots: Janux to receive up to $500.5M/ target as upfront and milestones along with royalties on sales of product emerges from the collaboration, making a total deal value ~$1B. Merck will fund R&D performed under the agreement Merck to get an exclusive WW license to products & IP developed from the collaboration The focus of …

Merck Signs a ~$1B Pact with Janux to Develop Cancer Therapies Using T Cell Engager Technology Read More »

5 big healthcare lawsuits of 2020

Some of the biggest legal stories of the year include patients attempting to mount a class action lawsuit against Mayo Clinic after an employee improperly viewed more than 1,600 health records and the Supreme Court hearing opening arguments in a case challenging the constitutionality of the ACA’s individual mandate.

Consumer awareness, needs generating shifts in precision medicine landscape  

Healthcare consumers are increasingly aware of specific therapies in development or on the market that can help treat the diseases they or their loved ones may be suffering from — and this growing awareness is changing the precision medicine arena.

Merck KGaA Collaborates with Iktos to Deploy AI in New Drug Design

Shots: Iktos will leverage its de novo generative design technology to be used in a structure-enabled context, facilitating the rapid & cost-effective design of Merck KGaA’s drug discovery program The collaboration follows the previous agreement of the companies signed in 2019. Merck KGaA is utilizing Iktos’ de novo design software platform Makya for MPO Iktos’ …

Merck KGaA Collaborates with Iktos to Deploy AI in New Drug Design Read More »

Novartis’s Branaplam (LMI070) Receives the US FDA’s Orphan Drug Designation for Huntington’s Disease

Shots: The US FDA has granted ODD for branaplam in HD. In preclinical trials, branaplam demonstrated a reduction in levels of the mutant huntingtin protein. Additionally, the therapy showed a reduction in huntingtin mRNA in SMA patients Novartis expects to initiate the P-IIb study for branaplam in HD patients in 2021 Branaplam (qw, PO) is …

Novartis’s Branaplam (LMI070) Receives the US FDA’s Orphan Drug Designation for Huntington’s Disease Read More »

Chugai Reports NDA Submission of Risdiplam to the MHLW as the First Oral Drug for SMA in Japan

Shots: The NDA submission is based on FIREFISH study assessing Risdiplam in infants with symptomatic SMA Type 1 & SUNFISH study in children and young adults with SMA Type 2 or 3 FIRESISH study results: improvement in survival and motor milestones in infants. SUNFISH study results: improvement in motor function in people aged 2-25 with …

Chugai Reports NDA Submission of Risdiplam to the MHLW as the First Oral Drug for SMA in Japan Read More »